Clifford Hudis

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
McArthur Heather L; Hudis Clifford A
Trastuzumab: a picky partner?
Sugarman Steven; Wasserheit Carolyn; Hodgman Elizabeth; Coglianese Maryellen; D'Alassandro Anne; Fournier Monica; Troso-Sandoval Tiffany; D'Andrea Gabriella; Drullinsky Pamela; Lake Diana; George Roshini; Mills Nancy; Moynahan Maryellen; Smith Joyce; Panageas Katherine; Norton Larry; Hudis Clifford
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
Muss Hyman B; Berry Donald A; Cirrincione Constance T; Theodoulou Maria; Mauer Ann M; Kornblith Alice B; Partridge Ann H; Dressler Lynn G; Cohen Harvey J; Becker Heather P; Kartcheske Patricia A; Wheeler Judith D; Perez Edith A; Wolff Antonio C; Gralow Julie R; Burstein Harold J; Mahmood Ahmad A; Magrinat Gustav; Parker Barbara A; Hart Ronald D; Grenier Debjani; Norton Larry; Hudis Clifford A; Winer Eric P;
Adjuvant chemotherapy in older women with early-stage breast cancer.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Clifford Hudis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: McArthur Heather L; Hudis Clifford A
Trastuzumab: a picky partner?
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(20):6311-3.
2009: Sugarman Steven; Wasserheit Carolyn; Hodgman Elizabeth; Coglianese Maryellen; D'Alassandro Anne; Fournier Monica; Troso-Sandoval Tiffany; D'Andrea Gabriella; Drullinsky Pamela; Lake Diana; George Roshini; Mills Nancy; Moynahan Maryellen; Smith Joyce; Panageas Katherine; Norton Larry; Hudis Clifford
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
Breast cancer research and treatment 2009;115(3):609-12.
2009: Muss Hyman B; Berry Donald A; Cirrincione Constance T; Theodoulou Maria; Mauer Ann M; Kornblith Alice B; Partridge Ann H; Dressler Lynn G; Cohen Harvey J; Becker Heather P; Kartcheske Patricia A; Wheeler Judith D; Perez Edith A; Wolff Antonio C; Gralow Julie R; Burstein Harold J; Mahmood Ahmad A; Magrinat Gustav; Parker Barbara A; Hart Ronald D; Grenier Debjani; Norton Larry; Hudis Clifford A; Winer Eric P;
Adjuvant chemotherapy in older women with early-stage breast cancer.
The New England journal of medicine 2009;360(20):2055-65.
2009: Theodoulou Maria; Batist Gerald; Campos Susana; Winer Eric; Welles Lauri; Hudis Clifford
Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer.
Clinical breast cancer 2009;9(2):101-7.
2009: Morris Patrick G; McArthur Heather L; Hudis Clifford A
Therapeutic options for metastatic breast cancer.
Expert opinion on pharmacotherapy 2009;10(6):967-81.
2009: Gonzalez-Angulo Ana M; Stemke-Hale Katherine; Palla Shana L; Carey Mark; Agarwal Roshan; Meric-Berstam Funda; Traina Tiffany A; Hudis Clifford; Hortobagyi Gabriel N; Gerald William L; Mills Gordon B; Hennessy Bryan T
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2472-8.
2009: Zhang Liying; Bacares Ruben; Boyar Sherry; Hudis Clifford; Nafa Khedoudja; Offit Kenneth
cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.
Mutation research 2009;663(1-2):84-9.
2009: Carlson Robert W; Allred D Craig; Anderson Benjamin O; Burstein Harold J; Carter W Bradford; Edge Stephen B; Erban John K; Farrar William B; Goldstein Lori J; Gradishar William J; Hayes Daniel F; Hudis Clifford A; Jahanzeb Mohammad; Kiel Krystyna; Ljung Britt-Marie; Marcom P Kelly; Mayer Ingrid A; McCormick Beryl; Nabell Lisle M; Pierce Lori J; Reed Elizabeth C; Smith Mary Lou; Somlo George; Theriault Richard L; Topham Neal S; Ward John H; Winer Eric P; Wolff Antonio C;
Breast cancer. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(2):122-92.
2009: Kimmick G G; Cirrincione C; Duggan D B; Bhalla K; Robert N; Berry D; Norton L; Lemke S; Henderson I C; Hudis C; Winer E;
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
Breast cancer research and treatment 2009;113(3):479-90.
2008: Dickler Maura N; Rugo Hope S; Eberle Carey A; Brogi Edi; Caravelli James F; Panageas Katherine S; Boyd Jeff; Yeh Benjamin; Lake Diana E; Dang Chau T; Gilewski Teresa A; Bromberg Jacqueline F; Seidman Andrew D; D'Andrea Gabriella M; Moasser Mark M; Melisko Michele; Park John W; Dancey Janet; Norton Larry; Hudis Clifford A
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7878-83.
2008: Subbaramaiah Kotha; Benezra Robert; Hudis Clifford; Dannenberg Andrew J
Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription.
The Journal of biological chemistry 2008;283(49):33955-68.
2008: Murphy Conleth; Hudis Clifford A; Dickler Maura N
Aromatase inhibitors and arthralgia: a growing pain?
Oncology (Williston Park, N.Y.) 2008;22(12):1424, 1426.
2008: Dang Chau; D'Andrea Gabriella; Lake Diana; Sugarman Steve; Fornier Monica; Moynahan Mary Ellen; Gilewski Theresa; Hurria Arti; Mills Nancy; Troso-Sandoval Tiffany; George Roshini; Robson Mark; Dickler Maura; Smith Karen; Panageas Katherine S; Norton Larry; Hudis Clifford A
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.
Clinical breast cancer 2008;8(5):418-24.
2008: Barginear M F; Van Poznak C; Rosen N; Modi S; Hudis C A; Budman D R
The heat shock protein 90 chaperone complex: an evolving therapeutic target.
Current cancer drug targets 2008;8(6):522-32.
2008: Traina T A; Poggesi I; Robson M; Asnis A; Duncan B A; Heerdt A; Dang C; Lake D; Moasser M; Panageas K; Borgen P; Norton L; Hudis C; Dickler M N
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Breast cancer research and treatment 2008;111(2):377-88.
2008: Dang Chau; Norton Larry; Hudis Clifford
Dose-dense chemotherapy with trastuzumab is an appropriate option.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3655-6; author reply 3656.
2008: Polite Blase N; Cirrincione Constance; Fleming Gini F; Berry Donald A; Seidman Andrew; Muss Hyman; Norton Larry; Shapiro Charles; Bakri Kamal; Marcom Kelly; Lake Diana; Schwartz Joel H; Hudis Clifford; Winer Eric P
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(16):2659-65.
2008: Hudis Clifford; Dang Chau
The taxane limbo: how low can we go?
Journal of the National Cancer Institute 2008;100(11):761-3.
2008: Liu Minetta C; Demetri George D; Berry Donald A; Norton Larry; Broadwater Gloria; Robert Nicholas J; Duggan David; Hayes Daniel F; Henderson I Craig; Lyss Alan; Hopkins Judith; Kaufman Peter A; Marcom P Kelly; Younger Jerry; Lin Nancy; Tkaczuk Katherine; Winer Eric P; Hudis Clifford A;
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
Cancer treatment reviews 2008;34(3):223-30.
2008: Kirk Margaret C; Hudis Clifford A
Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer.
Clinical breast cancer 2008;8(2):155-61.
2008: Traina Tiffany A; Theodoulou Maria; Feigin Kimberly; Patil Sujata; Tan K Lee; Edwards Charles; Dugan Ute; Norton Larry; Hudis Clifford
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(11):1797-802.
2008: Seidman Andrew D; Berry Donald; Cirrincione Constance; Harris Lyndsay; Muss Hyman; Marcom P Kelly; Gipson Grandella; Burstein Harold; Lake Diana; Shapiro Charles L; Ungaro Peter; Norton Larry; Winer Eric; Hudis Clifford
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(10):1642-9.
2008: Tan Lee K; Giri Dilip; Hummer Amanda J; Panageas Katherine S; Brogi Edi; Norton Larry; Hudis Clifford; Borgen Patrick I; Cody Hiram S
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(11):1803-9.
2008: Dang Chau; Fornier Monica; Sugarman Steven; Troso-Sandoval Tiffany; Lake Diana; D'Andrea Gabriella; Seidman Andrew; Sklarin Nancy; Dickler Maura; Currie Violante; Gilewski Theresa; Moynahan Mary Ellen; Drullinsky Pamela; Robson Mark; Wasserheit-Leiblich Carolyn; Mills Nancy; Steingart Richard; Panageas Katherine; Norton Larry; Hudis Clifford
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1216-22.
2008: Kauff Noah D; Domchek Susan M; Friebel Tara M; Robson Mark E; Lee Johanna; Garber Judy E; Isaacs Claudine; Evans D Gareth; Lynch Henry; Eeles Rosalind A; Neuhausen Susan L; Daly Mary B; Matloff Ellen; Blum Joanne L; Sabbatini Paul; Barakat Richard R; Hudis Clifford; Norton Larry; Offit Kenneth; Rebbeck Timothy R
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1331-7.
2008: Perez Edith A; Suman Vera J; Davidson Nancy E; Sledge George W; Kaufman Peter A; Hudis Clifford A; Martino Silvana; Gralow Julie R; Dakhil Shaker R; Ingle James N; Winer Eric P; Gelmon Karen A; Gersh Bernard J; Jaffe Allan S; Rodeheffer Richard J
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1231-8.
2008: Subbaramaiah Kotha; Hudis Clifford; Chang Sung-Hee; Hla Timothy; Dannenberg Andrew J
EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange.
The Journal of biological chemistry 2008;283(6):3433-44.
2008: Wright Jean L; Cordeiro Peter G; Ben-Porat Leah; Van Zee Kimberly J; Hudis Clifford; Beal Kathryn; McCormick Beryl
Mastectomy with immediate expander-implant reconstruction, adjuvant chemotherapy, and radiation for stage II-III breast cancer: treatment intervals and clinical outcomes.
International journal of radiation oncology, biology, physics 2008;70(1):43-50.
2008: McArthur Heather L; Hudis Clifford A
Advances in adjuvant chemotherapy of early stage breast cancer.
Cancer treatment and research 2008;141():37-53.
2007: McArthur Heather L; Hudis Clifford A
Dose-dense therapy in the treatment of early-stage breast cancer: an overview of the data.
Clinical breast cancer 2007;8 Suppl 1():S6-S10.
2007: Hudis Clifford; Modi Shanu
Preoperative chemotherapy for breast cancer: miracle or mirage?
JAMA : the journal of the American Medical Association 2007;298(22):2665-7.
2007: Deng Gary; Vickers Andrew; Yeung Simon; D'Andrea Gabriella M; Xiao Han; Heerdt Alexandra S; Sugarman Steven; Troso-Sandoval Tiffany; Seidman Andrew D; Hudis Clifford A; Cassileth Barrie
Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(35):5584-90.
2007: Modi Shanu; Stopeck Alison T; Gordon Michael S; Mendelson David; Solit David B; Bagatell Rochelle; Ma Weining; Wheler Jennifer; Rosen Neal; Norton Larry; Cropp Gillian F; Johnson Robert G; Hannah Alison L; Hudis Clifford A
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(34):5410-7.
2007: Hudis Clifford; McArthur Heather; Dang Chau
Current status of the taxanes as adjuvant therapy for breast cancer.
Breast (Edinburgh, Scotland) 2007;16 Suppl 2():S132-5.
2007: Krychman Michael L; Stelling Carla J; Carter Jeanne; Hudis Clifford A
A case series of androgen use in breast cancer survivors with sexual dysfunction.
The journal of sexual medicine 2007;4(6):1769-74.
2007: Hayes Daniel F; Thor Ann D; Dressler Lynn G; Weaver Donald; Edgerton Susan; Cowan David; Broadwater Gloria; Goldstein Lori J; Martino Silvana; Ingle James N; Henderson I Craig; Norton Larry; Winer Eric P; Hudis Clifford A; Ellis Matthew J; Berry Donald A;
HER2 and response to paclitaxel in node-positive breast cancer.
The New England journal of medicine 2007;357(15):1496-506.
2007: Fornier M N; Rathkopf D; Shah M; Patil S; O'Reilly E; Tse A N; Hudis C; Lefkowitz R; Kelsen D P; Schwartz G K
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5841-6.
2007: Muss Hyman B; Berry Donald A; Cirrincione Constance; Budman Daniel R; Henderson I Craig; Citron Marc L; Norton Larry; Winer Eric P; Hudis Clifford A;
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3699-704.
2007: McArthur Heather L; Hudis Clifford A
Has first-line therapy had an impact on general outcome in metastatic breast cancer?
Future oncology (London, England) 2007;3(4):411-8.
2007: Smith Karen Lisa; Adank Muriel; Kauff Noah; Lafaro Kelly; Boyd Jeff; Lee Johanna B; Hudis Clifford; Offit Kenneth; Robson Mark
BRCA mutations in women with ductal carcinoma in situ.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4306-10.
2007: Hudis Clifford A
Trastuzumab--mechanism of action and use in clinical practice.
The New England journal of medicine 2007;357(1):39-51.
2007: McArthur Heather L; Hudis Clifford A
Breast cancer chemotherapy.
Cancer journal (Sudbury, Mass.) 2007;13(3):141-7.
2007: Hudis Clifford A; Barlow William E; Costantino Joseph P; Gray Robert J; Pritchard Kathleen I; Chapman Judith-Anne W; Sparano Joseph A; Hunsberger Sally; Enos Rebecca A; Gelber Richard D; Zujewski Jo Anne
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):2127-32.
2007: Gilewski Teresa A; Ragupathi Govind; Dickler Maura; Powell Shemeeakah; Bhuta Sonal; Panageas Kathy; Koganty R Rao; Chin-Eng Jeannette; Hudis Clifford; Norton Larry; Houghton Alan N; Livingston Philip O
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):2977-85.
2007: Moore Halle C F; Green Stephanie J; Gralow Julie R; Bearman Scott I; Lew Danika; Barlow William E; Hudis Clifford; Wolff Antonio C; Ingle James N; Chew Helen K; Elias Anthony D; Livingston Robert B; Martino Silvana;
Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(13):1677-82.
2007: McArthur Heather L; Hudis Clifford A
Adjuvant chemotherapy for early-stage breast cancer.
Hematology/oncology clinics of North America 2007;21(2):207-22.
2007: Carlson Robert W; Anderson Benjamin O; Burstein Harold J; Carter W Bradford; Edge Stephen B; Farrar William B; Goldstein Lori J; Gradishar William J; Hayes Daniel F; Hudis Clifford A; Jahanzeb Mohammad; Ljung Britt-Marie; Kiel Krystyna; Marks Lawrence B; McCormick Beryl; Nabell Lisle M; Pierce Lori J; Reed Elizabeth C; Silver Samuel M; Smith Mary Lou; Somlo George; Theriault Richard L; Ward John H; Winer Eric P; Wolff Antonio C
Invasive breast cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(3):246-312.
2007: Hurria Arti; Naeim Arash; Elkin Elena; Limaye Sewanti; Grover Anjali; Hudis Clifford; Pearce Carol; Robson Mark
Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists.
Critical reviews in oncology/hematology 2007;61(3):255-60.
2007: Fornier Monica N; Seidman Andrew D; Lake Diana; D'Andrea Gabriella; Bromberg Jacqueline; Robson Mark; Van Poznak Catherine; Panageas Katherine S; Atienza Marietta; Norton Larry; Hudis Clifford
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(1):223-7.
2006: Chlebowski Rowan T; Blackburn George L; Thomson Cynthia A; Nixon Daniel W; Shapiro Alice; Hoy M Katherine; Goodman Marc T; Giuliano Armando E; Karanja Njeri; McAndrew Philomena; Hudis Clifford; Butler John; Merkel Douglas; Kristal Alan; Caan Bette; Michaelson Richard; Vinciguerra Vincent; Del Prete Salvatore; Winkler Marion; Hall Rayna; Simon Michael; Winters Barbara L; Elashoff Robert M
Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.
Journal of the National Cancer Institute 2006;98(24):1767-76.
2006: Rincon Mercedes; Broadwater Gloria; Harris Lyndsay; Crocker Abigail; Weaver Donald; Dressler Lynn; Berry Donald; Sutton Linda; Michaelson Richard; Messino Michael; Kirshner Jeffrey; Fleming Gini; Winer Eric; Hudis Clifford; Appel Stacy; Norton Larry; Muss Hyman;
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
Breast cancer research and treatment 2006;100(3):301-8.
2006: Carlson Robert W; Hudis Clifford A; Pritchard Kathy I;
Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(10):971-9.
2006: Hurria Arti; Fleming Mark T; Baker Sharyn D; Kelly Wm Kevin; Cutchall Katie; Panageas Katherine; Caravelli James; Yeung Henry; Kris Mark G; Gomez Jorge; Miller Vincent A; D'Andrea Gabriella; Scher Howard I; Norton Larry; Hudis Clifford
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6100-5.
2006: Modi Shanu; D'Andrea Gabriella; Norton Larry; Yao Tzy Jyun; Caravelli James; Rosen Peter P; Hudis Clifford; Seidman Andrew D
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.
Clinical breast cancer 2006;7(3):270-7.
2006: Hurria Arti; Goldfarb Shari; Rosen Carol; Holland Jimmie; Zuckerman Enid; Lachs Mark S; Witmer Matthew; van Gorp Wilfred G; Fornier Monica; D'Andrea Gabriella; Moasser Mark; Dang Chau; Van Poznak Catherine; Robson Mark; Currie Violante E; Theodoulou Maria; Norton Larry; Hudis Clifford
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.
Breast cancer research and treatment 2006;98(3):343-8.
2006: Hurria Arti; Hurria Anju; Zuckerman Enid; Panageas Katherine S; Fornier Monica; D'Andrea Gabriella; Dang Chau; Moasser Mark; Robson Mark; Seidman Andrew; Currie Violante; VanPoznak Catherine; Theodoulou Maria; Lachs Mark S; Hudis Clifford
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy.
Journal of the American Geriatrics Society 2006;54(7):1119-24.
2006: Carlson Robert W; Moench Susan J; Hammond M Elizabeth H; Perez Edith A; Burstein Harold J; Allred D Craig; Vogel Charles L; Goldstein Lori J; Somlo George; Gradishar William J; Hudis Clifford A; Jahanzeb Mohammad; Stark Azadeh; Wolff Antonio C; Press Michael F; Winer Eric P; Paik Soonmyung; Ljung Britt-Marie;
HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4 Suppl 3():S1-22; quiz S23-4.
2006: Dang Chau; Hudis Clifford
Can granulocyte-colony stimulating factor worsen anemia?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):2985-6.
2006: Burstein Harold J; Mayer Erica; Patridge Ann H; O'Kane Holly; Litsas Georgia; Come Steven E; Hudis Clifford A; Goldstein Donald F; Muss Hyman B; Winter Eric P; Garber Judy E
Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons.
Clinical breast cancer 2006;7(2):158-61.
2006: Hurria Arti; Rosen Carol; Hudis Clifford; Zuckerman Enid; Panageas Katherine S; Lachs Mark S; Witmer Matthew; van Gorp Wilfred G; Fornier Monica; D'Andrea Gabriella; Moasser Mark; Dang Chau; Van Poznak Catherine; Hurria Anju; Holland Jimmie
Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study.
Journal of the American Geriatrics Society 2006;54(6):925-31.
2006: Hudis Clifford A; Winer Eric P
Cancer and leukemia group B breast committee: decades of progress and plans for the future.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 2):3576s-80s.
2006: Doane A S; Danso M; Lal P; Donaton M; Zhang L; Hudis C; Gerald W L
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen.
Oncogene 2006;25(28):3994-4008.
2006: Subbaramaiah Kotha; Howe Louise R; Port Elisa R; Brogi Edi; Fishman Jack; Liu Catherine H; Hla Timothy; Hudis Clifford; Dannenberg Andrew J
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.
Cancer research 2006;66(10):5504-11.
2006: Dang Chau; Hudis Clifford
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
Clinical breast cancer 2006;7(1):51-8.
2006: Berry Donald A; Cirrincione Constance; Henderson I Craig; Citron Marc L; Budman Daniel R; Goldstein Lori J; Martino Silvana; Perez Edith A; Muss Hyman B; Norton Larry; Hudis Clifford; Winer Eric P
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
JAMA : the journal of the American Medical Association 2006;295(14):1658-67.
2006: Carlson Robert W; Brown Elizabeth; Burstein Harold J; Gradishar William J; Hudis Clifford A; Loprinzi Charles; Mamounas Eleftherios Paul; Perez Edith A; Pritchard Kathleen; Ravdin Peter; Recht Abram; Somlo George; Theriault Richard L; Winer Eric P; Wolff Antonio C;
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4 Suppl 1():S1-26.
2006: Hudis Clifford A
Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer.
Nature clinical practice. Oncology 2006;3(1):12-3.
2006: Van Poznak C; Cross S S; Saggese M; Hudis C; Panageas K S; Norton L; Coleman R E; Holen I
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Journal of clinical pathology 2006;59(1):56-63.
2005: Hortobagyi Gabriel N; de la Garza Salazar Jaime; Pritchard Kathleen; Amadori Dino; Haidinger Renate; Hudis Clifford A; Khaled Hussein; Liu Mei-Ching; Martin Miguel; Namer Moise; O'Shaughnessy Joyce A; Shen Zhen Zhou; Albain Kathy S;
The global breast cancer burden: variations in epidemiology and survival.
Clinical breast cancer 2005;6(5):391-401.
2005: Hudis Clifford
The best use of adjuvant chemotherapy: new drugs and new use of "old" drugs.
Breast (Edinburgh, Scotland) 2005;14(6):570-5.
2005: Howe Louise R; Chang Sung-Hee; Tolle Kelly C; Dillon Rachelle; Young Lawrence J T; Cardiff Robert D; Newman Robert A; Yang Peiying; Thaler Howard T; Muller William J; Hudis Clifford; Brown Anthony M C; Hla Timothy; Subbaramaiah Kotha; Dannenberg Andrew J
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice.
Cancer research 2005;65(21):10113-9.
2005: Hurria Arti; Gupta Supriya; Zauderer Marjorie; Zuckerman Enid L; Cohen Harvey J; Muss Hyman; Rodin Miriam; Panageas Katherine S; Holland Jimmie C; Saltz Leonard; Kris Mark G; Noy Ariela; Gomez Jorge; Jakubowski Ann; Hudis Clifford; Kornblith Alice B
Developing a cancer-specific geriatric assessment: a feasibility study.
Cancer 2005;104(9):1998-2005.
2005: Fornier Monica N; Modi Shanu; Panageas Katherine S; Norton Larry; Hudis Clifford
Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.
Cancer 2005;104(8):1575-9.
2005: Beal Kathryn; Hudis Clifford; Norton Larry; Wagman Raquel; McCormick Beryl
Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk?
The breast journal 2005;11(5):317-20.
2005: Elkin Elena B; Hudis Clifford; Begg Colin B; Schrag Deborah
The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999.
Cancer 2005;104(6):1149-57.
2005: Hudis Clifford
Testing chemotherapy for breast cancer: timing is everything.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5434-6.
2005: Hurria Arti; Brogan Kelly; Panageas Katherine S; Pearce Carol; Norton Larry; Jakubowski Ann; Zauderer Marjorie; Howard Jane; Hudis Clifford
Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Breast cancer research and treatment 2005;92(2):151-6.
2005: Hudis Clifford A; Vogel Charles L; Gralow Julie R; Williams Denise;
Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
Clinical breast cancer 2005;6(2):132-42.
2005: Carlson Robert W; Anderson Benjamin O; Burstein Harold J; Cox Charles E; Edge Stephen B; Farrar William B; Goldstein Lori J; Gradishar William J; Hayes Daniel F; Hudis Clifford; Jahanzeb Mohammad; Ljung Britt-Marie; Marks Lawrence B; McCormick Beryl; Nabell Lisle M; Pierce Lori J; Reed Elizabeth C; Silver Samuel M; Smith Mary Lou; Somlo George; Theriault Richard L; Ward John H; Winer Eric P; Wolff Antonio C;
Breast cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3(3):238-89.
2005: Hudis Clifford A
Clinical implications of antiangiogenic therapies.
Oncology (Williston Park, N.Y.) 2005;19(4 Suppl 3):26-31.
2005: Modi Shanu; Currie Violante E; Seidman Andrew D; Bach Ariadne M; Panageas Katherine S; Theodoulou Maria; Moasser Mark M; D'Andrea Gabriella M; Lake Diana E; Choi Jennifer; Norton Larry; Hudis Clifford A
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
Clinical breast cancer 2005;6(1):55-60.
2005: Modi Shanu; Seidman Andrew D; Dickler Maura; Moasser Mark; D'Andrea Gabriella; Moynahan Mary Ellen; Menell Jennifer; Panageas Katherine S; Tan Lee K; Norton Larry; Hudis Clifford A
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
Breast cancer research and treatment 2005;90(2):157-63.
2005: Lippman Marc E; Benz Chris; Chinnaiyan Arul; Flockhart David; Harris Adrian; Hudis Clifford; Osborne C Kent; Press Michael F; Rae James; Sledge George W; Van't Veer Laura; Wicha Max
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'.
Breast cancer research and treatment 2005;90(1):1-3.
2005: Muss Hyman B; Woolf Susan; Berry Donald; Cirrincione Constance; Weiss Raymond B; Budman Daniel; Wood William C; Henderson I Craig; Hudis Clifford; Winer Eric; Cohen Harvey; Wheeler Judith; Norton Larry;
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
JAMA : the journal of the American Medical Association 2005;293(9):1073-81.
2005: Fornier M N; Seidman A D; Schwartz M K; Ghani F; Thiel R; Norton L; Hudis C
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(2):234-9.
2005: Fornier Monica; Hudis Clifford
Adjuvant chemotherapy for primary breast cancer.
Current oncology reports 2005;7(1):18-22.
2005: Robson Mark; Svahn Tiffany; McCormick Beryl; Borgen Patrick; Hudis Clifford A; Norton Larry; Offit Kenneth
Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
Cancer 2005;103(1):44-51.
2005: Winer Eric P; Hudis Clifford; Burstein Harold J; Wolff Antonio C; Pritchard Kathleen I; Ingle James N; Chlebowski Rowan T; Gelber Richard; Edge Stephan B; Gralow Julie; Cobleigh Melody A; Mamounas Eleftherios P; Goldstein Lori J; Whelan Timothy J; Powles Trevor J; Bryant John; Perkins Cheryl; Perotti Judy; Braun Susan; Langer Amy S; Browman George P; Somerfield Mark R
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):619-29.
2005: Modi Shanu; DiGiovanna Michael P; Lu Zhao; Moskowitz Chaya; Panageas Katherine S; Van Poznak Catherine; Hudis Clifford A; Norton Larry; Tan Lee; Stern David F; Carter Darryl; Seidman Andrew D
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
Cancer investigation 2005;23(6):483-7.
2005: Hurria Arti; Hurria Anju; Brogan Kelly; Panageas Katherine S; Pearce Carol; Norton Larry; Jakubowski Ann; Howard Jane; Hudis Clifford
Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.
Drugs & aging 2005;22(9):785-91.
2005: Hurria Arti; Brogan Kelly; Panageas Katherine S; Jakubowski Ann; Zauderer Marjorie; Pearce Carol; Norton Larry; Howard Jane; Hudis Clifford
Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Drugs & aging 2005;22(8):709-15.
2004: Kattan Michael W; Giri Dilip; Panageas Katherine S; Hummer Amanda; Cranor Milicent; Van Zee Kimberly J; Hudis Clifford A; Norton Larry; Borgen Patrick I; Tan Lee K
A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy.
Cancer 2004;101(11):2509-15.
2004: Tripathy Debu; Seidman Andrew; Keefe Deborah; Hudis Clifford; Paton Virginia; Lieberman Grazyna
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
Clinical breast cancer 2004;5(4):293-8.
2004: Dang Chau T; D'Andrea Gabriella M; Moynahan Mary E; Dickler Maura N; Seidman Andrew D; Fornier Monica; Robson Mark E; Theodoulou Maria; Lake Diana; Currie Violante E; Hurria Arti; Panageas Katherine S; Norton Larry; Hudis Clifford A
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5754-61.
2004: Hughes Kevin S; Schnaper Lauren A; Berry Donald; Cirrincione Constance; McCormick Beryl; Shank Brenda; Wheeler Judith; Champion Lorraine A; Smith Thomas J; Smith Barbara L; Shapiro Charles; Muss Hyman B; Winer Eric; Hudis Clifford; Wood William; Sugarbaker David; Henderson I Craig; Norton Larry;
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.
The New England journal of medicine 2004;351(10):971-7.
2004: King Tari A; Ganaraj Archana; Fey Jane V; Tan Lee K; Hudis Clifford; Norton Larry; Cody Hiram S; Borgen Patrick I
Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy.
Cancer 2004;101(5):926-33.
2004: Dang Chau T; Dannenberg Andrew J; Subbaramaiah Kotha; Dickler Maura N; Moasser Mark M; Seidman Andrew D; D'Andrea Gabriella M; Theodoulou Maria; Panageas Katherine S; Norton Larry; Hudis Clifford A
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4062-7.
2004: Hudis Clifford A; Schmitz Norbert
Dose-dense chemotherapy in breast cancer and lymphoma.
Seminars in oncology 2004;31(3 Suppl 8):19-26.
2004: Winer Eric P; Berry Donald A; Woolf Susan; Duggan David; Kornblith Alice; Harris Lyndsay N; Michaelson Richard A; Kirshner Jeffrey A; Fleming Gini F; Perry Michael C; Graham Mark L; Sharp Stewart A; Keresztes Roger; Henderson I Craig; Hudis Clifford; Muss Hyman; Norton Larry
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2061-8.
2004: Lal Priti; Salazar Paulo A; Hudis Clifford A; Ladanyi Marc; Chen Beiyun
HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.
American journal of clinical pathology 2004;121(5):631-6.
2004: Theodoulou Maria; Hudis Clifford
Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
Cancer 2004;100(10):2052-63.
2004: Hudis Clifford A; Dang Chau T
Adjuvant therapy for breast cancer: practical lessons from the early breast cancer trialists' collaborative group.
Breast disease 2004;21():3-13.
2004: Ludwig Heinz; Hudis Clifford A; Goss Glen; Leyland-Jones Brian
Epoetin alfa: future directions and future research.
The oncologist 2004;9 Suppl 5():70-3.
2004: Hudis Clifford A; Van Belle Simon; Chang Jose; Muenstedt Karsten
rHuEPO and treatment outcomes: the clinical experience.
The oncologist 2004;9 Suppl 5():55-69.
2004: Lake Diana E; Hudis Clifford A
High-dose chemotherapy in breast cancer.
Drugs 2004;64(17):1851-60.
2004: Robson Mark E; Chappuis Pierre O; Satagopan Jaya; Wong Nora; Boyd Jeff; Goffin John R; Hudis Clifford; Roberge David; Norton Larry; Bégin Louis R; Offit Kenneth; Foulkes William D
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Breast cancer research : BCR 2004;6(1):R8-R17.
2003: Dang Chau T; Fornier Monica N; Hudis Clifford A
Risk models for neutropenia in patients with breast cancer.
Oncology (Williston Park, N.Y.) 2003;17(11 Suppl 11):14-20.
2003: Hudis Clifford A
Current status and future directions in breast cancer therapy.
Clinical breast cancer 2003;4 Suppl 2():S70-5.
2003: Hurria Arti; Hudis Clifford
Follow-up care of breast cancer survivors.
Critical reviews in oncology/hematology 2003;48(1):89-99.
2003: Hurria Arti; Leung Denis; Trainor Kathleen; Norton Larry; Hudis Clifford
Screening chest imaging studies are not effective in the follow-up of breast cancer patients.
The Journal of oncology management : the official journal of the American College of Oncology Administrators 2003;12(5):13-5.
2003: Bartelink Harry; Benz Christopher; Cleveland Don; Dorn Ronald; Gralow Julie; Gradishar William J; Grant Kathleen; Heimann Ruth; Hellman Samuel; Hudis Clifford; Kerbel Robert; Lippman Marc; Lung John; Posner Mitchell C; Steeg Patricia; Vestal Robert; Weichselbaum Ralph R; Zetter Bruce
Expedition Inspiration Fund for Breast Cancer Research Meeting 2003.
Breast cancer research and treatment 2003;80(2):139-44.
2003: Winer Eric P; Hudis Clifford; Burstein Harold J; Bryant John; Chlebowski Rowan T; Ingle James N; Edge Stephen B; Mamounas Eleftherios P; Gelber Richard; Gralow Julie; Goldstein Lori J; Pritchard Kathleen I; Braun Susan; Cobleigh Melody A; Langer Amy S; Perotti Judy; Powles Trevor J; Whelan Timothy J; Browman George P
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2597-9.
2003: Hurria Arti; Leung Denis; Trainor Kathleen; Borgen Patrick; Norton Larry; Hudis Clifford
Factors influencing treatment patterns of breast cancer patients age 75 and older.
Critical reviews in oncology/hematology 2003;46(2):121-6.
2003: Citron Marc L; Berry Donald A; Cirrincione Constance; Hudis Clifford; Winer Eric P; Gradishar William J; Davidson Nancy E; Martino Silvana; Livingston Robert; Ingle James N; Perez Edith A; Carpenter John; Hurd David; Holland James F; Smith Barbara L; Sartor Carolyn I; Leung Eleanor H; Abrams Jeffrey; Schilsky Richard L; Muss Hyman B; Norton Larry
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1431-9.
2003: Kauff Noah D; Brogi Edi; Scheuer Lauren; Pathak Dorothy R; Borgen Patrick I; Hudis Clifford A; Offit Kenneth; Robson Mark E
Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations.
Cancer 2003;97(7):1601-8.
2003: Buzdar Aman; O'Shaughnessy Joyce A; Booser Daniel J; Pippen John E; Jones Stephen E; Munster Pamela N; Peterson Patrick; Melemed Allen S; Winer Eric; Hudis Clifford
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1007-14.
2002: Hudis Clifford
Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
Clinical breast cancer 2002;3(5):326-32.
2002: Lake Diana E; Hudis Clifford
Aromatase inhibitors in breast cancer: an update.
Cancer control : journal of the Moffitt Cancer Center 2002;9(6):490-8.
2002: Hudis Clifford A
Single-agent vs combination therapy in advanced breast cancer: potential roles of capecitabine.
Oncology (Williston Park, N.Y.) 2002;16(10 Suppl 12):13-6.
2002: Hudis Clifford
Breast cancer and leukemia: the forest for the trees?
Annals of surgical oncology 2002;9(8):717-8.
2002: Howe Louise R; Subbaramaiah Kotha; Patel Jay; Masferrer Jaime L; Deora Aparna; Hudis Clifford; Thaler Howard T; Muller William J; Du Baoheng; Brown Anthony M C; Dannenberg Andrew J
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
Cancer research 2002;62(19):5405-7.
2002: Modi Shanu; Panageas Katherine S; Duck Elaine T; Bach Ariadne; Weinstock Nancy; Dougherty James; Cramer Laura; Hudis Clifford; Norton Larry; Seidman Andrew
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(17):3665-73.
2002: Winer Eric P; Hudis Clifford; Burstein Harold J; Chlebowski Rowan T; Ingle James N; Edge Stephen B; Mamounas Eleftherios P; Gralow Julie; Goldstein Lori J; Pritchard Kathleen I; Braun Susan; Cobleigh Melody A; Langer Amy S; Perotti Judy; Powles Trevor J; Whelan Timothy J; Browman George P
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(15):3317-27.
2002: Dang Chau T; Shapiro Charles L; Hudis Clifford A
Potential role of selective COX-2 inhibitors in cancer management.
Oncology (Williston Park, N.Y.) 2002;16(5 Suppl 4):30-6.
2002: Kauff Noah D; Satagopan Jaya M; Robson Mark E; Scheuer Lauren; Hensley Martee; Hudis Clifford A; Ellis Nathan A; Boyd Jeff; Borgen Patrick I; Barakat Richard R; Norton Larry; Castiel Mercedes; Nafa Khedoudja; Offit Kenneth
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
The New England journal of medicine 2002;346(21):1609-15.
2002: Van Poznak Catherine; Tan Lee; Panageas Katherine S; Arroyo Crispinita D; Hudis Clifford; Norton Larry; Seidman Andrew D
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2319-26.
2002: Seidman Andrew; Hudis Clifford; Pierri Mary Kathryn; Shak Steven; Paton Virginia; Ashby Mark; Murphy Maureen; Stewart Stanford J; Keefe Deborah
Cardiac dysfunction in the trastuzumab clinical trials experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1215-21.
2001: Fornier M N; Seidman A D; Theodoulou M; Moynahan M E; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas K S; Norton L; Hudis C
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3934-41.
2001: Weiss R B; Gill G G; Hudis C A
An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2771-7.
2001: Seidman A D; Fornier M N; Esteva F J; Tan L; Kaptain S; Bach A; Panageas K S; Arroyo C; Valero V; Currie V; Gilewski T; Theodoulou M; Moynahan M E; Moasser M; Sklarin N; Dickler M; D'Andrea G; Cristofanilli M; Rivera E; Hortobagyi G N; Norton L; Hudis C A
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(10):2587-95.
2001: Van Poznak C; Seidman A D; Reidenberg M M; Moasser M M; Sklarin N; Van Zee K; Borgen P; Gollub M; Bacotti D; Yao T J; Bloch R; Ligueros M; Sonenberg M; Norton L; Hudis C
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial.
Breast cancer research and treatment 2001;66(3):239-48.
2001: Münster P N; Buzdar A; Dhingra K; Enas N; Ni L; Major M; Melemed A; Seidman A; Booser D; Theriault R; Norton L; Hudis C
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):2002-9.
2001: Gilewski T; Ragupathi G; Bhuta S; Williams L J; Musselli C; Zhang X F; Bornmann W G; Spassova M; Bencsath K P; Panageas K S; Chin J; Hudis C A; Norton L; Houghton A N; Livingston P O; Danishefsky S J
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(6):3270-5.
2001: Recht A; Edge S B; Solin L J; Robinson D S; Estabrook A; Fine R E; Fleming G F; Formenti S; Hudis C; Kirshner J J; Krause D A; Kuske R R; Langer A S; Sledge G W; Whelan T J; Pfister D G;
Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1539-69.
2001: Ajani J; Ettinger D; Kelsen D P; Hudis C; Kudelka A; Langer C; Pienta K; Safran H; Vokes E E; Yung W K;
Radiation Therapy Oncology Group. Research Plan 2002-2006. Medical Oncology Committee.
International journal of radiation oncology, biology, physics 2001;51(3 Suppl 2):88-91.
2001: McCormick B; Strom E; Craighead P S; Kuske R; Hudis C; Ley J; Margolis L; Meyerwitz B; Morris E; Petrek J; Pierce L; Pisansky T; Rabinovitch R; Sneige N; Vicini F; Unger D; Winter K;
Radiation Therapy Oncology Group. Research Plan 2002-2006. Breast Cancer Working Group.
International journal of radiation oncology, biology, physics 2001;51(3 Suppl 2):56-7.
2000: Barakat R R; Gilewski T A; Almadrones L; Saigo P E; Venkatraman E; Hudis C; Hoskins W J
Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3459-63.
2000: Hudis C
Dose-dense chemotherapy for breast cancer: the story so far.
British journal of cancer 2000;82(12):1897-9.
2000: Donnelly J M; Kornblith A B; Fleishman S; Zuckerman E; Raptis G; Hudis C A; Hamilton N; Payne D; Massie M J; Norton L; Holland J C
A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners.
Psycho-oncology 2000;9(1):44-56.
2000: Gilewski T; Seidman A; Norton L; Hudis C
An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service.
Cancer chemotherapy and pharmacology 2000;46 Suppl():S23-6.
2000: Münster P N; Hudis C A
Role of taxanes in adjuvant therapy.
Cancer investigation 2000;18(1):32-8.
1999: Robson M; Levin D; Federici M; Satagopan J; Bogolminy F; Heerdt A; Borgen P; McCormick B; Hudis C; Norton L; Boyd J; Offit K
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
Journal of the National Cancer Institute 1999;91(24):2112-7.
1999: Liberman L; Zakowski M F; Avery S; Hudis C; Morris E A; Abramson A F; LaTrenta L R; Glassman J R; Dershaw D D
Complete percutaneous excision of infiltrating carcinoma at stereotactic breast biopsy: how can tumor size be assessed?
AJR. American journal of roentgenology 1999;173(5):1315-22.
1999: Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz C C; Dantis L; Sklarin N T; Seidman A D; Hudis C A; Moore J; Rosen P P; Twaddell T; Henderson I C; Norton L
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Seminars in oncology 1999;26(4 Suppl 12):78-83.
1999: Hudis C; Fornier M; Riccio L; Lebwohl D; Crown J; Gilewski T; Surbone A; Currie V; Seidman A; Reichman B; Moynahan M; Raptis G; Sklarin N; Theodoulou M; Weiselberg L; Salvaggio R; Panageas K S; Yao T J; Norton L
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1118.
1999: Münster P N; Hudis C A
Adjuvant therapy for resectable breast cancer.
Hematology/oncology clinics of North America 1999;13(2):391-413, vi.
1999: Hudis C A
The current state of adjuvant therapy for breast cancer: focus on paclitaxel.
Seminars in oncology 1999;26(1 Suppl 2):1-5.
1999: Hudis C A; Münster P N
High-dose therapy for breast cancer.
Seminars in oncology 1999;26(1):35-47.
1999: D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan M E; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton M A; Yao T J; Seidman A D
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):275-9.
1999: Hudis C; Seidman A; Baselga J; Raptis G; Lebwohl D; Gilewski T; Moynahan M; Sklarin N; Fennelly D; Crown J P; Surbone A; Uhlenhopp M; Riedel E; Yao T J; Norton L
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):93-100.
1998: Seidman A D; Hudis C A; Albanell J; Tong W; Tepler I; Currie V; Moynahan M E; Theodoulou M; Gollub M; Baselga J; Norton L
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3353-61.
1998: Hudis C A
Dose-dense paclitaxel-containing adjuvant therapy for breast cancer.
Oncology (Williston Park, N.Y.) 1998;12(1 Suppl 1):16-8.
1998: Hudis C; Riccio L; Seidman A; Baselga J; Currie V; Fennelly D; Gilewski T; Lebwohl D; Moynahan M; Raptis G; Surbone A; Sklarin N; Yao T J; Keefe D; Norton L
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.
Cancer investigation 1998;16(2):67-71.
1997: Hudis C; Riccio L; Holmes F; Seidman A; Baselga J; Currie V; Fennelly D; Gilewski T; Moynahan M; Raptis G; Sklarin N; Surbone A; Uhlenhopp M; Maickel N; Yao T J; Hellmann S; Usakewicz J; Hortobagyi G; Norton L
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(13):2198-202.
1997: Seidman A D; Hudis C A; McCaffrey J; Tong W; Currie V; Moynahan M E; Theodoulou M; Tepler I; Gollub M; Norton L
Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.
Seminars in oncology 1997;24(5 Suppl 17):S17-72-S17-76.
1997: Hudis C A; Borgen P
Systemic treatment for stage I and stage II breast cancer.
Surgical oncology clinics of North America 1997;6(4):683-98.
1997: Hudis C
Sequential dose-dense adjuvant therapy with doxorubicin, paclitaxel, and cyclophosphamide.
Oncology (Williston Park, N.Y.) 1997;11(4 Suppl 3):15-8.
1997: Seidman A D; Hudis C A; Raptis G; Baselga J; Fennelly D; Norton L
Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience.
Oncology (Williston Park, N.Y.) 1997;11(3 Suppl 2):20-8.
1997: Hoff P M; Valero V; Holmes F A; Whealin H; Hudis C; Hortobagyi G N
Paclitaxel-induced pancreatitis: a case report.
Journal of the National Cancer Institute 1997;89(1):91-3.
1996: Hudis C A; Norton L
Adjuvant drug therapy for operable breast cancer.
Seminars in oncology 1996;23(4):475-93.
1996: Hudis C A
Cyclophosphamide, methotrexate, and fluorouracil: still the gold standard?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(7):1971-3.
1996: Seidman A D; Hochhauser D; Gollub M; Edelman B; Yao T J; Hudis C A; Francis P; Fennelly D; Gilewski T A; Moynahan M E; Currie V; Baselga J; Tong W; O'Donaghue M; Salvaggio R; Auguste L; Spriggs D; Norton L
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1877-84.
1996: Hudis C
New approaches to adjuvant chemotherapy for breast cancer.
Pharmacotherapy 1996;16(3 Pt 2):88S-93S.
1996: Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz C C; Dantis L; Sklarin N T; Seidman A D; Hudis C A; Moore J; Rosen P P; Twaddell T; Henderson I C; Norton L
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):737-44.
1996: Hudis C; Seidman A; Raptis G; Fennelly D; Gilewski T; Baselga J; Theodoulou M; Sklarin N; Moynahan M; Surbone A; Currie V; Lebwohl D; Uhlenhopp M; Crown J; Norton L
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.
Seminars in oncology 1996;23(1 Suppl 1):58-64.
1996: Hudis C A; Seidman A D; Crown J P; Balmaceda C; Freilich R; Gilewski T A; Hakes T B; Currie V; Lebwohl D E; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):58-65.
1995: Crown J; Raptis G; Hamilton N; Hudis C; Vahclat L; Fennelly D; Norton L
High-dose chemotherapy of breast cancer.
The Canadian journal of oncology 1995;5 Suppl 1():80-2.
1995: Hudis C A; Seidman A D; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan M E; Sklarin N; Fennelly D
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Seminars in oncology 1995;22(6 Suppl 15):18-23.
1995: Vahdat L; Raptis G; Fennelly D; Hamilton N; Reich L; Tiersten A; Harrison M; Hudis C; Moore M; Yao T J
Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(11):1267-73.
1995: Seidman A D; Tiersten A; Hudis C; Gollub M; Barrett S; Yao T J; Lepore J; Gilewski T; Currie V; Crown J
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(10):2575-81.
1995: Seidman A D; Hudis C A; Fennelly D; Raptis G; Baselga J; Norton L
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer.
Seminars in oncology 1995;22(5 Suppl 12):108-16.
1995: DiLorenzo T A; Jacobsen P B; Bovbjerg D H; Chang H; Hudis C A; Sklarin N T; Norton L
Sources of anticipatory emotional distress in women receiving chemotherapy for breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(7):705-11.
1995: Seidman A D; Hudis C A; Norton L
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy.
Seminars in oncology 1995;22(4 Suppl 8):3-8.
1995: Seidman A D; Reichman B S; Crown J P; Yao T J; Currie V; Hakes T B; Hudis C A; Gilewski T A; Baselga J; Forsythe P
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(5):1152-9.
1995: Jacobsen P B; Bovbjerg D H; Schwartz M D; Hudis C A; Gilewski T A; Norton L
Conditioned emotional distress in women receiving chemotherapy for breast cancer.
Journal of consulting and clinical psychology 1995;63(1):108-14.
1994: Seidman A D; Norton L; Reichman B S; Crown J P; Yao T J; Hakes T B; Lebwohl D E; Gilewski T A; Hudis C A; Surbone A
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer.
Oncology 1994;51 Suppl 1():33-9.
1994: Hudis C
Is there an alternative to alternating adjuvant therapy for breast cancer?
Cancer investigation 1994;12(3):329-35.
1994: Hudis C A
Do we need a "stopping rule" for breast cancer?
Cancer investigation 1994;12(5):543-4.
1993: Hudis C A; Norton L
Systemic adjuvant therapy for breast cancer.
Current opinion in oncology 1993;5(6):982-90.
1993: Crown J; Vahdat L; Fennelly D; Francis P; Wasserheit C; Hudis C; Kritz A; Schneider J; Hamilton N; Gilewski T
High-intensity chemotherapy with hematopoietic support in breast cancer.
Annals of the New York Academy of Sciences 1993;698():378-88.
1993: Reichman B S; Seidman A D; Crown J P; Heelan R; Hakes T B; Lebwohl D E; Gilewski T A; Surbone A; Currie V; Hudis C A
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(10):1943-51.
1993: Crown J; Kritz A; Vahdat L; Reich L; Moore M; Hamilton N; Schneider J; Harrison M; Gilewski T; Hudis C
Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(6):1144-9.
1993: Crown J; Hakes T; Reichman B; Lebwohl D; Gilewski T; Surbone A; Currie V; Yao T J; Hudis C; Seidman A
Phase II trial of carboplatin and etoposide in metastatic breast cancer.
Cancer 1993;71(4):1254-7.
1992: Bovbjerg D H; Redd W H; Jacobsen P B; Manne S L; Taylor K L; Surbone A; Crown J P; Norton L; Gilewski T A; Hudis C A
An experimental analysis of classically conditioned nausea during cancer chemotherapy.
Psychosomatic medicine 1992;54(6):623-37.
1992: Hudis C A; Kelsen D P
Menogaril in the treatment of malignant mesothelioma: a phase II study.
Investigational new drugs 1992;10(2):103-6.
1991: Kelsen D; Hudis C; Niedzwiecki D; Dougherty J; Casper E; Botet J; Vinciguerra V; Rosenbluth R
A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.
Cancer 1991;68(5):965-9.
1987: Hudis C A
Expanding medical horizons: an overseas rotation.
American College of Physicians observer 1987;7(4):18.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Clifford Hudis

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Clifford Hudis (preview)

All Publications